halobetasol propionate and tazarotene


( Last Updated : June 19, 2019)
Generic Name:
halobetasol propionate and tazarotene
Project Status:
Withdrawn
Therapeutic Area:
Psoriasis, moderate to severe plaque
Manufacturer:
Bausch Health, Canada Inc.
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0600-000

Details


Manufacturer Requested Reimbursement Criteria1:
Topical treatment of moderate-to-severe plaque psoriasis.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Psoriasis, moderate to severe plaque
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedJanuary 07, 2019
Submission receivedFebruary 04, 2019
Clarification:

- Voluntarily withdrawn by the manufacturer on 2019-Feb-19